Endo Reschedules Release of Fourth Quarter and Full Year 2024 Earnings Results and Conference Call
Rhea-AI Summary
Endo (OTCQX: NDOI) has announced the rescheduling of its fourth quarter and full year 2024 financial results release to March 13, 2025, before market open. The company will host a conference call at 8:00 a.m. ET on the same day.
Investors can access the audio webcast through the Investor Relations section of Endo's website at investor.endo.com under Events & Presentations. Conference call participants can dial 800-836-8184 (U.S. and Canada toll-free) or 646-357-8785 (international). Participants should join 10 minutes before the scheduled start time. A webcast replay will be available after the event.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, NDOI declined 1.40%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
The audio webcast may be accessed through the Investor Relations section of the Company's website at investor.endo.com under Events & Presentations. To access the call through a conference line, participants may dial 800-836-8184 (
About Endo
Endo is a diversified pharmaceutical company boldly transforming insights into life-enhancing therapies. Our passionate team members collaborate to develop and deliver these essential medicines. Together, we are committed to helping everyone we serve live their best life. Learn more at www.endo.com or connect with us on LinkedIn.
View original content to download multimedia:https://www.prnewswire.com/news-releases/endo-reschedules-release-of-fourth-quarter-and-full-year-2024-earnings-results-and-conference-call-302397491.html
SOURCE Endo, Inc.